

<p style="text-align: center;">Modified 1449/PTO</p> <p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: center;">(use as many sheets as necessary)</p>				Complete if Known	
				Application Number:	
				Filing Date:	
				First Named Inventor:	Harry Leneau
				Group Art Unit:	
				Examiner Name:	
Sheet	1	of	3	Attorney Docket Number:	503775.008

Sheet	1	of	3
-------	---	----	---

Application Number:	
Filing Date:	
First Named Inventor:	Harry Leneau
Group Art Unit:	
Examiner Name:	
Attorney Docket Number:	503775.008

[illegible][illegible][illegible]

Examiner Signature		Date Considered	4/1/2007
-----------------------	---	--------------------	----------

Submission of these references is not an admission that the references constitute prior art.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Modified 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number:	
		Filing Date:	
		First Named Inventor:	Harry Leneau
		Group Art Unit:	
Examiner Name:		Attorney Docket Number:	503775.008
Sheet	2	of	3

 09/586510
 06/02/00

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS AND INFORMATION			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MBI	1	W.L. RAGLAND, DVM, PhD, et al., "Passive Immunotherapy of Equine Respiratory Disease: Treatment of Acutely Ill Horses With Equine Immunoglobulin," The Equine Athlete, November/December 1995, Vol. 8, No. 6, pp. 1-6.	
MBI	2	STEVEN B. CONSTANT, DVM, et al., "Serum immunoglobulin G concentration in goat kids fed colostrum or a colostrum substitute," JAVMA, December 15, 1994, Vol. 205, No. 12, pp. 1759-1762	
MBI	3	JOHN E. VAN WYE, M.D., et al., "Pseudomonas Hyperimmune Globulin Passive Immunotherapy for Pulmonary Exacerbations in Cystic Fibrosis," Pediatric Pulmonology, (1990), Vol. 9, pp. 7-18	
MBI	4	B. BAKER, et al., "Endotoxaemia in Racehorses Following Exertion," Journal of the South African Veterinary Association, June 1988, pp. 63-66	
MBI	5	ALAN JOHNSTONE, et al., "Immunochemistry in Practice," Blackwell Sci. Pub., 1987, pp. 33-34	
MBI	6	BEVERLY L. MANGOLD and DAVID A. DEAN, "Passive Transfer with Serum and IgG Antibodies of Irradiated Cercaria-Induced Resistance Against Schistosoma Mansoni in Mice," The Journal of Immunology, April 1, 1986, Vol. 136, No. 7, pp. 2644-2648	
MBI	7	MASAYUKI IWATA, et al., "Antipyretic activity of human immunoglobulin preparations for intravenous use in an experimental model of fever in rabbits," Clinical Use of Intravenous Immunoglobulins, 1986, pp. 327-338, Academic Press Inc. (London) Ltd.	
MBI	8	VAL G. HEMMING, et al., "Immunoglobulins in respiratory syncytial virus infections," Clinical Use of Intravenous Immunoglobulins, 1986, pp. 285-294, Academic Press Inc. (London) Ltd.	
MBI	9	T. NISHIMURA and R. FUJII, "Therapeutic evaluation of combination therapy with immunoglobulin (IG-100) and antibiotics against severe paediatric infections," Clinical Use of Intravenous Immunoglobulins, 1986, pp. 367-372, Academic Press Inc. (London) Ltd.	
MBI	10	K. MATSUMOTO, et al., "Therapeutic evaluation of combination therapy with immunoglobulin (IG-100) and antibiotics against severe infections," Clinical Use of Intravenous Immunoglobulins, 1986, pp. 363-366, Academic Press Inc. (London) Ltd.	
MBI	11	MATTHEW POLLACK, "Antibody therapy in Gram-negative bacterial disease," Clinical Use of Intravenous Immunoglobulins, 1986, pp. 317-326, Academic Press Inc. (London) Ltd.	
MBI	12	MICHAEL P. GLAUSER and J.D. BAUMGARTNER, "Septicaemia and shock in Gram-negative bacterial infections," Clinical Use of Intravenous Immunoglobulins, 1986, pp. 355-362, Academic Press Inc. (London) Ltd.	
MBI	13	J. BUSSELL, et al., "Prophylaxis of neonatal sepsis with intravenous gammaglobulin," Clinical Use of Intravenous Immunoglobulins, 1986, pp. 171-175, Academic Press Inc. (London) Ltd.	

Examiner Signature		Date Considered	4/1/2002
--------------------	---	-----------------	----------

Submission of these references is not an admission that the references constitute prior art.


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

09/506510
JCS31 W.S. P139.

[illegible]

Examiner Signature		Date Considered	4/1/2000
-----------------------	---	--------------------	----------

Submission of these references is not an admission that the references constitute prior art.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**